Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
CMS
Pharma
Biogen, Eisai submit comments opposing CMS' AD coverage draft
CMS' Aduhelm coverage proposal risks duplicating the role of the FDA, sans the authority and scientific know-how, Eisai said Thursday.
Fraiser Kansteiner
Feb 10, 2022 1:07pm
Biogen's Aduhelm pulls in only $3M in 2021
Feb 3, 2022 9:30am
Medicare received majority of comments iffy on Biogen's Aduhelm
Feb 1, 2022 11:34am
CMS' Aduhelm decision could bleed through to rivals
Feb 1, 2022 9:45am
CMS draft 'could effectively spell the end' for Aduhelm: analyst
Jan 12, 2022 8:30am
‘Anything that starts’ to cover Aduhelm is good: Biogen CEO
Jan 10, 2022 12:05pm
